Trait | COVID-19 subjects (N = 90) | Controls (N = 50) |
---|---|---|
Gender; Male/ Female (N, %) | 48 (53.3%)/ 42 (46.7%) | 28 (56%)/ 22 (44%) |
Smoker/ Non-smoker | 41 (45.5%)/ 49 (54.5%) | 21 (42%)/ 29 (58%) |
Age (Year, mean ± SD) | 49.2 ± 13.4 | 48.3 ± 12.6 |
Duration of COVID-19 (Day) | 10.9 ± 1.4 | – |
Oxygen saturation | 91.8 ± 7.1 | – |
Systolic BP (mmHg) | 138.7 ± 20.4 | – |
Diastolic BP (mmHg) | 75.8 ± 9.9 | – |
WBC (cells/mm3) | 9451 ± 1877.3 | – |
Neutrophil–lymphocyte ratio | 10.4 ± 6.9 | – |
ALP (IU/L) | 244.8 ± 42.9 | – |
AST (IU/L) | 35.7 ± 11.3 | – |
ALT (IU/L) | 36.4 ± 7.5 | – |
LDH (IU/L) | 408.2 ± 97.1 | – |
CRP (mg/L) | 5.1 ± 1.2 | – |
ESR (mm/h) | 22.7 ± 10.3 | – |
BMI (kg/m2) | 27.9 ± 7.1 | – |
Total cholesterol (mg/dl) | 223.2 ± 41.9 | – |
TG (mg/dl) | 173.7 ± 51.5 | – |
LDL (mg/dl) | 144.2 ± 35.6 | – |
HDL (mg/dl) | 49.2 ± 14.1 | – |
Creatinine (mg/dl) | 1.87 ± 0.49 | – |
BUN (mg/dl) | 24.4 ± 13.2 | – |
FBS (mg/dl) | 101.5 ± 32.7 | – |
D-dimer (ng/ml) | 1.74 ± 0.21 | – |
Cardiovascular diseases | 12 (13.3%) | – |
Diabetes | 11 (12.2%) | – |
Hypertension | 16 (17.8%) | – |
Fever | 60 (66.6%) | – |
Cough | 59 (65.5%) | – |
Dyspnea | 55 (61.1%) | – |
Sputum | 39 (43.3%) | – |
Vomiting/diarrhea | 33 (36.7%) | – |
Methylprednisolone use | 29 (32.2%) | – |
Remdesivir use | 21 (23.3%) | – |
Azithromycin use | 12 (13.3%) | – |
Anticoagulation therapy | 16 (17.8%) | – |